Business Context and Reporting Period
This Form 8-K reports on the Annual General Meeting (AGM) of Bicycle Therapeutics plc held on June 17, 2025. The company is incorporated in England and Wales and its American Depositary Shares (ADS) trade on The Nasdaq Stock Market LLC under the symbol BCYC. The filing details the voting results for nine ordinary resolutions presented to shareholders.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting; it does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing references the adoption of U.K. statutory annual accounts for the year ended December 31, 2024, but does not disclose the specific figures within this document.
Material Changes and Voting Results
Shareholders representing approximately 98.63% of issued and outstanding ordinary shares (49,135,059 shares) participated in the AGM. All nine proposals were passed. Key voting outcomes include:
- Director Re-elections: Alessandro Riva and Stephen Sands were re-elected. Proposal 1 (Riva) received 40,034,345 votes "For" versus 9,086,349 "Against." Proposal 2 (Sands) received 47,652,747 votes "For" versus 1,481,237 "Against."
- Executive Compensation: The advisory vote on named executive officer compensation (Proposal 3) passed with 47,287,428 "For" votes against 1,743,008 "Against" votes.
- Auditor Ratification: PricewaterhouseCoopers LLP was ratified as the U.S. independent registered public accounting firm (Proposal 4) and re-appointed as U.K. statutory auditors (Proposal 5) with overwhelming support (over 99% "For" in both cases).
- Equity Plan Amendment: An amendment to the Amended and Restated 2020 Equity Incentive Plan (Proposal 9) was approved with 38,137,068 "For" votes against 10,979,123 "Against" votes.
- Financial Statements: The U.K. statutory annual accounts and reports for the year ended December 31, 2024, were adopted (Proposal 7).
Guidance, Outlook, and Risks
This filing does not provide management guidance, future outlook, or specific risk factors. It serves solely to disclose the results of the shareholder vote. The filing notes that detailed descriptions of the proposals and voting procedures are contained in the definitive proxy statement on Schedule 14A filed on April 23, 2025.
Investor Verification Checklist
- Verify the specific financial figures for the year ended December 31, 2024, in the referenced U.K. statutory annual accounts (Proposal 7) and the Schedule 14A proxy statement.
- Review the details of the amendment to the 2020 Equity Incentive Plan (Proposal 9) to understand changes to share reserve or vesting terms.
- Confirm the full text of the directors' remuneration report for 2024 (Proposal 8) as referenced in the proxy statement.
- Note the significant "Against" vote count for the re-election of Alessandro Riva (approx. 18.5% of votes cast) and the Equity Plan amendment (approx. 22.3% of votes cast) as potential indicators of shareholder sentiment.